PhytoHealth CEO Angel Lee Recognized for Cancer Fatigue Drug Advancement

PhytoHealth Corporation CEO Angel Lee has been named one of Taiwan's 27th Ten Outstanding Young Women, an award that highlights her work in advancing PG2® Lyo. Injection. PG2® is the world's first approved prescription drug specifically for moderate to severe cancer-related fatigue (CRF).

The drug, derived from refined polysaccharides of the medicinal plant Astragalus membranaceus, is also Taiwan's first approved botanical new drug. It is utilized in Taiwanese medical institutions for CRF management and is covered by Taiwan's National Health Insurance (NHI) for eligible breast cancer patients.

CRF is a debilitating condition that has historically been underrecognized and undertreated. PhytoHealth has actively worked with Taiwan's medical community to increase awareness and promote the clinical management of CRF, contributing to the development of the island's first clinical guidelines for the condition.

PhytoHealth is currently seeking international pharmaceutical and healthcare partners to advance the global development of PG2® and its botanical drug platform, aiming to bring Taiwanese biotechnology innovations to global markets.